Vanda Pharmaceuticals Inc. (VM4)
XFRA 
Summary
VM4 Chart
Vanda Pharmaceuticals: Commercial Execution Meets Pipeline Optionality
Vanda Pharmaceuticals stands at a pivotal point, leveraging strong Fanapt growth and a robust late-stage pipeline for future expansion. VNDA's aggressive investment in commercial infrastructure has driven 31% Fanapt sales growth, but resulted in higher cash burn and quarterly losses. Key regulatory catalysts loom with PDUFA dates for Bysanti and tradipitant, and tradipitant's GLP-1 adjunct potential offers significant upside.
VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects
Vanda Pharmaceuticals stock rallies after phase II data show tradipitant sharply cuts Wegovy-related nausea and vomiting in overweight and obese adults.
Vanda Pharmaceuticals Inc. (VNDA) Q3 2025 Earnings Call Transcript
Vanda Pharmaceuticals Inc. ( VNDA ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Kevin Moran - Senior VP, CFO & Treasurer Mihael Polymeropoulos - Founder, President, CEO & Chairman of The Board Conference Call Participants Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Olivia Brayer - Cantor Fitzgerald & Co., Research Division Presentation Operator Hello, and thank you for standing by.
Vanda Pharmaceuticals Inc. (VM4) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Vanda Pharmaceuticals Inc. ever had a stock split?
Vanda Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mihael H. Polymeropoulos CEO | XFRA Exchange | US9216591084 ISIN |
| US Country | 368 Employees | - Last Dividend | - Last Split | 12 Apr 2006 IPO Date |
Overview
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for addressing high unmet medical needs on a global scale. With a focus on conditions that affect sleep-wake disorders, schizophrenia, and a variety of other medical conditions, Vanda Pharmaceuticals seeks to improve the quality of life for patients worldwide. Since its incorporation in 2002, and headquartered in Washington, D.C., the company has made significant strides in bringing novel treatments to the market and continues to expand its robust pipeline of promising therapeutic candidates.
Products and Services
- HETLIOZ (tasimelteon) – Marketed for the treatment of non-24-hour sleep-wake disorders. The pipeline for HETLIOZ includes potential applications for:
- Jet lag disorder
- Insomnia
- Delayed sleep phase disorder
- Sleep disturbances in autism spectrum disorder
- Pediatric Non-24
- Fanapt (iloperidone) oral tablets – Marketed for the treatment of schizophrenia, with ongoing development for:
- Bipolar I disorder
- Parkinson's disease psychosis
- A long-acting injectable (LAI) formulation for schizophrenia
- Tradipitant (VLY-686) – A small molecule neurokinin-1 receptor (NK-1R) antagonist in development for:
- Gastroparesis
- Motion sickness
- Atopic dermatitis
- COVID-19 pneumonia
- VTR-297 – A small molecule histone deacetylase inhibitor being studied for:
- Hematologic malignancies
- Various oncology indications
- VQW-765 – A small molecule nicotinic acetylcholine receptor partial agonist under investigation for:
- Performance anxiety
- Psychiatric disorders
- VHX-896 – An active metabolite of iloperidone in development.
- Antisense Oligonucleotide Molecules – Under investigation for various indications.
- Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activators and Inhibitors, including:
- VSJ-110 for the treatment of dry eye and ocular inflammation
- VPO-227 for treating secretory diarrhea disorders such as cholera
Contact Information
